708 related articles for article (PubMed ID: 12606628)
21. Possible involvement of dynorphin A-(1-17) release via mu1-opioid receptors in spinal antinociception by endomorphin-2.
Mizoguchi H; Watanabe H; Hayashi T; Sakurada W; Sawai T; Fujimura T; Sakurada T; Sakurada S
J Pharmacol Exp Ther; 2006 Apr; 317(1):362-8. PubMed ID: 16394196
[TBL] [Abstract][Full Text] [Related]
22. Opioid peptide-derived analgesics.
Schiller PW
AAPS J; 2005 Oct; 7(3):E560-5. PubMed ID: 16353933
[TBL] [Abstract][Full Text] [Related]
23. Involvement of spinal release of α-neo-endorphin on the antinociceptive effect of TAPA.
Mizoguchi H; Kon-No T; Watanabe H; Watanabe C; Yonezawa A; Sato T; Sakurada T; Sakurada S
Peptides; 2013 Dec; 50():139-44. PubMed ID: 24126280
[TBL] [Abstract][Full Text] [Related]
24. Altered opioid-mediated control of the spinal release of dynorphin and met-enkephalin in polyarthritic rats.
Ballet S; Mauborgne A; Hamon M; Cesselin F; Collin E
Synapse; 2000 Sep; 37(4):262-72. PubMed ID: 10891863
[TBL] [Abstract][Full Text] [Related]
25. delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice.
Hosohata Y; Vanderah TW; Burkey TH; Ossipov MH; Kovelowski CJ; Sora I; Uhl GR; Zhang X; Rice KC; Roeske WR; Hruby VJ; Yamamura HI; Lai J; Porreca F
Eur J Pharmacol; 2000 Feb; 388(3):241-8. PubMed ID: 10675732
[TBL] [Abstract][Full Text] [Related]
26. [Met]enkephalin in the spinal cord is involved in the antinociception induced by intracerebroventricularly-administered etorphine in the mouse.
Xu JY; Tseng LF
Neuroscience; 1997 Sep; 80(2):579-85. PubMed ID: 9284359
[TBL] [Abstract][Full Text] [Related]
27. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
28. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
29. Differential antinociception induced by spinally administered endomorphin-1 and endomorphin-2 in the mouse.
Ohsawa M; Mizoguchi H; Narita M; Nagase H; Kampine JP; Tseng LF
J Pharmacol Exp Ther; 2001 Aug; 298(2):592-7. PubMed ID: 11454920
[TBL] [Abstract][Full Text] [Related]
30. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
31. Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.
Ko MC; Lee H; Harrison C; Clark MJ; Song HF; Naughton NN; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2003 Jul; 306(1):179-86. PubMed ID: 12676881
[TBL] [Abstract][Full Text] [Related]
32. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
Nakayama D; Watanabe C; Watanabe H; Mizoguchi H; Sakurada T; Sakurada S
Eur J Pharmacol; 2007 Jun; 563(1-3):109-16. PubMed ID: 17343845
[TBL] [Abstract][Full Text] [Related]
33. Possible involvement of dynorphin A release via mu1-opioid receptor on supraspinal antinociception of endomorphin-2.
Sakurada S; Sawai T; Mizoguchi H; Watanabe H; Watanabe C; Yonezawa A; Morimoto M; Sato T; Komatsu T; Sakurada T
Peptides; 2008 Sep; 29(9):1554-60. PubMed ID: 18571771
[TBL] [Abstract][Full Text] [Related]
34. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
35. Involvement of endogenous opioid peptides in the antinociception induced by the novel dermorphin tetrapeptide analog amidino-TAPA.
Mizoguchi H; Watanabe C; Watanabe H; Moriyama K; Sato B; Ohwada K; Yonezawa A; Sakurada T; Sakurada S
Eur J Pharmacol; 2007 Apr; 560(2-3):150-9. PubMed ID: 17307162
[TBL] [Abstract][Full Text] [Related]
36. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
37. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
[TBL] [Abstract][Full Text] [Related]
38. Differential sensitivities of mouse strains to morphine and [Dmt1]DALDA analgesia.
Neilan CL; King MA; Rossi G; Ansonoff M; Pintar JE; Schiller PW; Pasternak GW
Brain Res; 2003 Jun; 974(1-2):254-7. PubMed ID: 12742645
[TBL] [Abstract][Full Text] [Related]
39. Bioactivity of new mu and delta opioid peptides.
Capasso A
Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
[TBL] [Abstract][Full Text] [Related]
40. A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse.
Watanabe H; Nakayama D; Ito K; Watanabe C; Mizoguchi H; Fujimura T; Murayama K; Kawamura S; Sato T; Sakurada C; Sakurada T; Sakurada S
J Pharmacol Exp Ther; 2005 Mar; 312(3):1075-81. PubMed ID: 15561796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
